StreetAlpha.app
Home › Stocks › BBIO

BridgeBio Pharma, Inc. (BBIO)

Healthcare
$76.80
▼ −0.72%
LAST CLOSE · NOV 17

BridgeBio Pharma develops medicines for patients with genetic diseases, with its main product being Attruby for a heart condition. It last closed at $76.80 on Nov 17, down 0.72% on the day. BBIO last reported earnings on Thu, Oct 29, 2026. The average 12-month price target from 8 analysts is $112.13 (+46.0% from the last close), with a high of $156.00 and a low of $91.00. Analyst consensus is Strong Buy, based on the latest ratings from 8 firms (8 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 2 whale options trades in BBIO, 50% of them bullish and 50% bearish. In the past 30 days there were 3 dark pool prints totaling $5.1M, the largest $2.0M.

AI Auto Pilots
Is BBIO in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$945.5M
+167.3% vs a year ago
Net income
−$573.8M
−60.7% margin
EPS (diluted)
−$3.03
Free cash flow
−$369.8M
−39.1% margin
Valuation
Market cap
$15.0B
194.8M shares
P/E
–
No P/E while losing money
Price to sales
15.8
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$1.5B
At Sep 30
Debt
$2.6B
At Sep 30
Shareholder equity
−$1.7B
Buybacks
$252.5M
Last 12 months
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $69.7M$69.7MFY2021FY2022: $77.6M$77.6MFY2022FY2023: $9.3M$9.3MFY2023FY2024: $221.9M$221.9MFY2024FY2025: $502.1M$502.1MFY2025

From BBIO's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 29). Last 12 months adds up the four latest quarters.

Last report
Oct 29
2026 · After the close (AMC)
Reported EPS
-$0.42
vs -$0.60 est. · beat
Year-ago EPS
—
Not on file
Options-implied move
±9.5%
Priced in before that report
Analyst consensus
Strong Buy
Based on 8 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
8firms
8 Buy0 Hold0 Sell
Each firm's latest rating on BBIO in the past 90 days
Average 12-month target
$112.13
▲ 46.0% upside

Based on 8 analysts who set a price target on BBIO in the past 90 days. The average target is $112.13, with a high of $156.00 and a low of $91.00, compared with the last close of $76.80.

Low $91.00Avg $112.13High $156.00
Blue marker: last close $76.80
Highest target$156.00
Average target$112.13
Lowest target$91.00
Latest rating changes
Morgan StanleyTarget raised
Nov 13Buy$88 → $91
Canaccord GenuityTarget raised
Nov 2Buy$106 → $108
TD CowenTarget lowered
Oct 30Buy$110 → $100
Morgan StanleyTarget raised
Oct 30Buy$87 → $88
Morgan StanleyTarget lowered
Oct 21Buy$97 → $87
DateFirmActionRatingPrice target
Nov 13Morgan StanleyTarget raisedBuy$88 → $91
Nov 2Canaccord GenuityTarget raisedBuy$106 → $108
Oct 30TD CowenTarget loweredBuy$110 → $100
Oct 30Morgan StanleyTarget raisedBuy$87 → $88
Oct 21Morgan StanleyTarget loweredBuy$97 → $87
Loading…

Technical Analysis

BBIO · as of the Nov 17 close · updated after every close
Turning up

The stock is 4% above its 20 day and 9% above its 50 day average. It is 5% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 60). The nearest support is the Pivot at $76.22, and the nearest resistance the swing high (Sep 9) at $76.81.

Short trendBullish
Long trendNeutral
MomentumStrong
StretchNormal
VolatilityNormal, 3.5%/day
Key levels
$93.4252 week high+21.6%
$77.68Pivot R1+1.1%
$76.81Swing high (Sep 9)+0.0%
$76.80Last close
$76.22Pivot−0.8%
$75.38100 day average−1.8%
$75.33Pivot S1−1.9%
$75.02Swing low (Aug 31)−2.3%
$74.0320 day average−3.6%
$72.69200 day average−5.4%
$70.0750 day average−8.8%
$62.5052 week low−18.6%
Indicators
RSI (14)59.54Middle of its rangeNeutral
MACD2.42Above its signal lineBullish
Stochastic71.3Middle of its rangeNeutral
ADX (14)38.5Trending up
Williams %R-37.9Oversold below −80, overbought above −20Neutral
CCI (20)43.3Oversold below −100, overbought above 100Neutral
Rate of change+3.7%Change over 10 sessionsBullish
ATR (14)$2.66Typical daily range, 3.5% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for BBIO

What happened before

See how BBIO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow BBIO usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How BBIO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
2
Bullish
1
50%
Bearish
1
50%
Date span
Aug 20 – Sep 9
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
3
Notional
$5.1M
Largest print
$2.0M
Loading…

BBIO Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲259 buying vs 225 selling
  • ▲Held by funds +17.4 pts
  • ▼Funds holding -11
  • ▼Superinvestors: 2 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding481492−2.2%
In funds' top 1012120.0%
Held by funds124.6%107.2%+17.4 pts
New / increased65 / 19483 / 174+0.8%
Reduced / sold out150 / 75168 / 77−8.2%
Put/call ratio6.030.31+1861.5%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See BBIO institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BBIO is in one of them and how their past BBIO trades turned out.

BBIO in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered BBIO in an article yet. Here's the latest on the wider market.

BBIO Congress Trades

All congress trades →
Trades, 12 months
9
Buys
8
89%
Sells
1
11%
People
2
Last filed Nov 10
Who traded BBIO · since 2025
Latest 5 filings of 11
$1K – $15KTraded Nov 2, 2026Filed Nov 10, 2026
$1K – $15KTraded Oct 27, 2026Filed Nov 10, 2026
Gilbert CisnerosSell (partial)
$1K – $15KTraded Sep 29, 2026Filed Oct 12, 2026
$1K – $15KTraded May 18, 2026Filed Jul 1, 2026
$1K – $15KTraded May 11, 2026Filed Jun 8, 2026
PersonTypeAmountTradedFiledDelay
Gilbert CisnerosD · CABuy$1K – $15KNov 2, 2026Nov 10, 20268 d
Gilbert CisnerosD · CABuy$1K – $15KOct 27, 2026Nov 10, 202614 d
Gilbert CisnerosD · CASell (partial)$1K – $15KSep 29, 2026Oct 12, 202613 d
Donald J TrumpExecutive branchBuy$1K – $15KMay 18, 2026Jul 1, 202644 d
Gilbert CisnerosD · CABuy$1K – $15KMay 11, 2026Jun 8, 202628 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About BridgeBio Pharma

BridgeBio Pharma is a biopharmaceutical company based in Palo Alto, California, that develops medicines for people with genetic diseases. Its main commercial product is Attruby, a treatment for a heart condition caused by transthyretin amyloidosis, sold in the United States. The same medicine is sold under another name in Europe and Japan through partners. The company is also developing treatments for other rare conditions, such as achondroplasia and muscular dystrophy, for patients, physicians and healthcare providers.

Headquarters
Palo Alto, CA